(Q40181544)

18 September 2017

title

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model (English)

1 reference

malignant peripheral nerve sheath tumor

18 September 2017

main subject

0 references

xenograft

1 reference

adult malignant schwannoma

inferred from title

1 reference

1 reference

Yonatan Y Mahller

1

1 reference

18 September 2017

Sachin S Vaikunth

2

1 reference

18 September 2017

Mark A Currier

3

1 reference

18 September 2017

Shyra J Miller

4

1 reference

18 September 2017

Maria C Ripberger

5

1 reference

18 September 2017

Ya-Hsuan Hsu

6

1 reference

18 September 2017

Ruty Mehrian-Shai

7

1 reference

18 September 2017

Margaret H Collins

8

1 reference

18 September 2017

Timothy M Crombleholme

9

1 reference

18 September 2017

Nancy Ratner

10

1 reference

18 September 2017

Timothy P Cripe

11

1 reference

18 September 2017

publication date

1 February 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

15

1 reference

18 September 2017

issue

2

1 reference

18 September 2017

page(s)

279-286

1 reference

Pathophysiology of neurofibromatosis type 1.

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Oncolytic viral therapies - the clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Nf1 haploinsufficiency augments angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Targeting neovascular pericytes in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Nf1 has an essential role in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Antiangiogenesis in neurofibromatosis 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Angiogenic and invasive properties of neurofibroma Schwann cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300038

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300038

1 reference

18 September 2017

1 reference